Cost effectiveness of an aromatase inhibitor and recombinant FSH versus FSH alone in older patients undergoing intrauterine insemination.

被引：0
|
作者：
Bedaiwy, MA [1 ]
Forman, R [1 ]
Casper, RF [1 ]
机构：
[1] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
FERTILITY AND STERILITY | 2005年 / 84卷
关键词：
D O I：
10.1016/j.fertnstert.2005.07.101
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 36 条
  • [31] Recombinant FSH therapy alone versus combination therapy with recombinant LH therapy in patients down-regulated with a low-dose luteal GnRH agonist protocol: preliminary results
    Kelly, EE
    Nebiolo, L
    TOWARDS REPRODUCTIVE CERTAINTY: FERTILITY & GENETICS BEYOND 1999, 1999, : 200 - 204
  • [32] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
    Guzauskas, G. F.
    Wang, B. C. M.
    Pollom, E. L.
    Stieber, V. W.
    Kinzel, A.
    Proescholdt, C.
    Garrison, L.
    NEURO-ONCOLOGY, 2018, 20 : 254 - 254
  • [33] COST EFFECTIVENESS OF TREATING GLIOBLASTOMA PATIENTS AGE 65 YEARS OR OLDER WITH TUMOR TREATING FIELDS PLUS TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE
    Guzauskas, Gregory
    Wang, Bruce C. M.
    Pollom, Erqi
    Stieber, Volker W.
    Garrison, Lou
    NEURO-ONCOLOGY, 2018, 20 : 116 - 117
  • [34] A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment
    Popovic-Todorovic, B
    Loft, A
    Bredkjæer, HE
    Bangsboll, S
    Nielsen, IK
    Andersen, AN
    HUMAN REPRODUCTION, 2003, 18 (11) : 2275 - 2282
  • [35] Recombinant FSH therapy alone (Gonal-F®) versus combination therapy (Gonal-F® plus r-hLH) in patients down regulated with a low dose luteal GnRH agonist protocol:: Preliminary results
    Kelly, E
    Nebiolo, L
    11TH WORLD CONGRESS ON IN VITRO FERTILIZATION AND HUMAN REPRODUCTIVE GENETICS, 1999, : 243 - 249
  • [36] Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2-metastatic breast cancer: A SEER-Medicare analysis
    Brufsky, Adam
    Sandin, Rickard
    Stergiopoulos, Stella
    Chen, Connie
    Karanth, Siddharth
    Li, Benjamin
    Esterberg, Lizzi
    Makari, Doris
    Candrilli, Sean D.
    Goyal, Ravi K.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
1234